MX2018004112A - Terapia de combinacion racional para el tratamiento de cancer. - Google Patents
Terapia de combinacion racional para el tratamiento de cancer.Info
- Publication number
- MX2018004112A MX2018004112A MX2018004112A MX2018004112A MX2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- agents
- combination therapy
- rational combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237470P | 2015-10-05 | 2015-10-05 | |
| PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004112A true MX2018004112A (es) | 2018-06-20 |
Family
ID=57145064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004112A MX2018004112A (es) | 2015-10-05 | 2016-10-05 | Terapia de combinacion racional para el tratamiento de cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180280397A1 (enExample) |
| EP (1) | EP3359196B1 (enExample) |
| JP (1) | JP7132848B2 (enExample) |
| KR (1) | KR20180058824A (enExample) |
| CN (1) | CN108472376A (enExample) |
| AU (1) | AU2016336351A1 (enExample) |
| BR (1) | BR112018006572A2 (enExample) |
| CA (1) | CA3000851A1 (enExample) |
| EA (1) | EA201890623A1 (enExample) |
| IL (1) | IL258494A (enExample) |
| MA (1) | MA47474A (enExample) |
| MX (1) | MX2018004112A (enExample) |
| TW (1) | TW201722422A (enExample) |
| WO (1) | WO2017062520A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
| US20240371465A1 (en) * | 2023-05-02 | 2024-11-07 | National Central University | Method, system, and computer readable medium for post-translational modifications detection |
| CN116813622B (zh) * | 2023-05-19 | 2026-02-03 | 中国科学院基础医学与肿瘤研究所(筹) | 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004512381A (ja) | 2000-11-02 | 2004-04-22 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法 |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| ES2624982T3 (es) | 2011-07-08 | 2017-07-18 | Sloan-Kettering Institute For Cancer Research | Usos de inhibidores etiquetados HSP90 |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
-
2016
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja not_active Expired - Fee Related
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en not_active Ceased
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko not_active Withdrawn
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3359196B1 (en) | 2022-03-16 |
| MA47474A (fr) | 2019-12-25 |
| EP3359196A1 (en) | 2018-08-15 |
| WO2017062520A1 (en) | 2017-04-13 |
| CA3000851A1 (en) | 2017-04-13 |
| BR112018006572A2 (pt) | 2018-10-09 |
| EA201890623A1 (ru) | 2018-09-28 |
| JP7132848B2 (ja) | 2022-09-07 |
| JP2018537519A (ja) | 2018-12-20 |
| IL258494A (en) | 2018-05-31 |
| US20180280397A1 (en) | 2018-10-04 |
| KR20180058824A (ko) | 2018-06-01 |
| TW201722422A (zh) | 2017-07-01 |
| AU2016336351A1 (en) | 2018-05-10 |
| CN108472376A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EP4656246A3 (en) | Combination therapies for the treatment of cancer | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX2017007321A (es) | Terapias de combinacion. | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| BR112017000556A2 (pt) | terapia de combinação para câncer | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 |